Effects of risperidone injection: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of risperidone injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of risperidone injection: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of risperidone injection: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Several studies have shown that risperidone injection is an effective treatment for patients with schizophrenia or schizoaffective disorder. 1 found that risperidone injection improved both positive and negative symptoms in stable patients with schizophrenia or schizoaffective disorder. 4 indicated that long-acting risperidone injection was effective in elderly patients with schizophrenia. 8 suggested that using risperidone injection could potentially reduce hospitalization time and healthcare costs. Furthermore, 7 revealed that risperidone injection was more effective in improving symptoms in hospitalized patients compared to conventional oral or long-acting antipsychotics. These studies suggest that risperidone injection is a promising treatment option for schizophrenia.

Benefits and Risks

Benefit Summary

Risperidone injection may offer the following benefits in treating schizophrenia and schizoaffective disorder: • Improved positive and negative symptoms • Reduced hospitalization time • Lowered healthcare costs • Enhanced medication compliance • More effective in symptom improvement compared to conventional oral or long-acting antipsychotics

Risk Summary

Risperidone injection may pose the following risks: • Weight gain • Metabolic abnormalities • Extrapyramidal symptoms • Neuroleptic malignant syndrome • Tardive dyskinesia • Cardiovascular events • Angioedema • Worsening of myasthenia gravis 2 • Higher risk of death compared to clozapine 5

Comparison Across Studies

Similarities

Many studies have shown that risperidone injection is effective for patients with schizophrenia or schizoaffective disorder. These studies suggest that risperidone injection can improve symptoms, reduce hospitalization time, and decrease healthcare costs.

Differences

There may be variations in the effectiveness and side effects of risperidone injection across studies. For example, 1 showed effectiveness in stable patients, while 7 demonstrated its superiority over conventional antipsychotics in hospitalized patients. Additionally, 9 suggested that risperidone injection is more cost-effective compared to other antipsychotics, but 13 found it to enhance amphetamine-induced conditioned place preference. These discrepancies may be attributed to differences in study design, patient populations, and assessment methods.

Consistency and Contradictions in Findings

Research findings on the effectiveness and safety of risperidone injection exhibit both consistency and contradictions. Numerous studies support the improvement of symptoms in schizophrenia and schizoaffective disorder with risperidone injection. However, inconsistencies arise in research findings regarding side effects. Some studies have shown potential weight gain and metabolic abnormalities associated with risperidone injection, while others haven't observed these side effects. These inconsistencies can be attributed to variations in study design, patient populations, and evaluation methods.

Considerations for Real-World Application

Risperidone injection may be a beneficial treatment for patients with schizophrenia or schizoaffective disorder. However, it's crucial to remember the potential side effects such as weight gain, metabolic abnormalities, and extrapyramidal symptoms. When considering risperidone injection, carefully discuss the risks and benefits with your doctor.

Limitations of Current Research

Research on the effectiveness and safety of risperidone injection is still limited. In particular, data on long-term effectiveness and safety is lacking. Further research is needed to understand how risperidone injection compares to other antipsychotics.

Future Research Directions

Research is required to evaluate the long-term effectiveness and safety of risperidone injection. Studies comparing the effectiveness and safety of risperidone injection with other antipsychotics are also crucial. Further research is needed to develop methods for preventing or mitigating side effects associated with risperidone injection.

Conclusion

Risperidone injection holds potential as an effective treatment for patients with schizophrenia or schizoaffective disorder. However, it's important to be aware of potential side effects such as weight gain, metabolic abnormalities, and extrapyramidal symptoms. When considering risperidone injection, consult with your doctor to carefully weigh the risks and benefits. Research is needed to evaluate the long-term effectiveness and safety of risperidone injection, compare it to other antipsychotics, and develop strategies for preventing or reducing side effects.

Literature analysis of 13 papers
Positive Content
7
Neutral Content
0
Negative Content
6
Article Type
3
0
0
2
13
1.

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Author: SimpsonGeorge M, MahmoudRamy A, LasserRobert A, KujawaMary, BossieCynthia A, TurkozIbrahim, RodriguezSteven, GharabawiGeorges M

Improved functioning
Low relapse

Long-acting risperidone was associated with low relapse and rehospitalization rates in patients with schizophrenia or schizoaffective disorder. Doses of 25 to 50 mg were appropriate for long-term treatment.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution.

Author: Al-HashelJasem Y, IsmailIsmail Ibrahim, JohnJohn K, IbrahimMohammed, AliMahmoud

Worsening myasthenia gravis

This is a case report of worsening myasthenia gravis after receiving long-acting risperidone injection for schizophrenia. This suggests that long-acting risperidone should be used with caution in patients with myasthenia gravis.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.

Author: TaylorDavid M, Douglas-HallPetrina, OlofinjanaBanke, WhiskeyEromona, ThomasArwel

Adverse effects
Increased death risk

Clozapine use was associated with a significantly increased risk of death compared to risperidone long-acting injection. Adverse effects and death were common reasons for discontinuation of clozapine.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

Author: SimpsonGeorge M, MahmoudRamy A, LasserRobert A, KujawaMary, BossieCynthia A, TurkozIbrahim, RodriguezSteven, GharabawiGeorges M

Improved functioning
Low relapse

Long-acting risperidone was associated with low relapse and rehospitalization rates in patients with schizophrenia or schizoaffective disorder. Doses of 25 to 50 mg were appropriate for long-term treatment.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.

Author: BaiY M, ChenT T, WuB, HungC H, LinW K, HuT M, LinC-Y, ChouP

Superiority of RLAI

Previous studies have demonstrated the superiority of risperidone long-acting injection (RLAI) over oral antipsychotics. This study investigated whether this superiority holds true in hospitalized patients with optimal drug compliance.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Health resource utilization associated with switching to risperidone long-acting injection.

Author: YoungC L, TaylorD M

Increased bed stay
Increased healthcare cost

Switching to risperidone long-acting injection (RLAI) was associated with a continuation of the trend for increased bed stay and use of healthcare resources.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Author: LauxGerd, HeegBart, van HoutBen A, MehnertAngelika

Treats Schizophrenia

Long-acting risperidone was more effective and less costly than haloperidol depot or oral olanzapine in treating schizophrenia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Resistance to excessive bodyweight gain in risperidone-injected rats.

Author: OtaMiyuki, MoriKeiji, NakashimaAkira, KanekoYoko S, TakahashiHisahide, OtaAkira

Increased thermogenesis
Hypothermia

Risperidone administration in rats resulted in hypothermia and lower bodyweight gain despite increased diet uptake. This effect was associated with upregulation of genes involved in heat production and lipid metabolism.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Long-acting risperidone injection.

Author: LoveRaymond C, ConleyRobert J

Improved clinical outcome
Improved quality of life
Reduced prolactin levels
Weight gain

Long-acting risperidone injection was found to be effective and well tolerated in patients with schizophrenia and schizoaffective disorder. It provided sustained plasma levels of risperidone, leading to continued clinical improvement and an increase in health-related quality of life.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference.

Author: BardgettMark E, DownnenTyler, CraneCasey, Baltes ThompsonEmily C, MuncieBrittany, SteffenSara A, YatesJustin R, PaulyJames R

Amphetamine sensitivity
Locomotor activity

This study found that chronic risperidone treatment during development in rats increased locomotor activity and sensitivity to the rewarding effects of amphetamine in adulthood. This effect may be due to a decrease in forebrain dopamine transporter density.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.